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Purpose: This review article examines the prevalence, etiology, and current therapies of dry 
eye disease, with special focus on postmenopausal women.
Method: A systematic literature search utilizing MEDLINE was conducted to identify peer-
reviewed articles related to dry eye published prior to September 2008. The terms “dry eye” and 
“women” were searched in combination with one or more of the following words or phrases: 
prevalence, postmenopausal, etiology, risk factors, therapy, medications, surgery, tear film, and 
quality of life. Articles were selected based on their direct applicability to the subject matter. 
A manual search was also conducted based on citations in the published literature.
Results: Epidemiologic studies identified prevalence rates ranging from 7% in the United 
States to 33% in Taiwan and Japan. Risk factors include advanced age, female sex, smoking, 
extreme heat or cold weather conditions, low relative humidity, use of video display terminals, 
refractive surgery, contact lens wear, and certain medications.
Conclusion: The last decade has brought about a better understanding of the etiology of dry 
eye disease. New therapies that can alleviate the signs and symptoms of dry eye disease and, 
consequently, improve the quality of life of dry eye patients are available in the market.
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Overview
Dry eye disease (DED) is one of the most frequently encountered ocular 
morbidities. Twenty-five percent of patients who visit ophthalmic clinics report 
symptoms of dry eye, making it a growing public health problem and one of the 
most common conditions seen by eye care practitioners.1 Historically, the term 
“Keratoconjunctivitis sicca” can be attributed to the Swedish ophthalmologist 
Henrik SC Sjögren.2 He was the first to refer to the triad of Keratoconjunctivitis 
sicca, dry mouth, and joint pain, which occurs mainly in women (90% of the 
cases) (www.sjogrens.org/), and in 1950 Andrew De Roetth introduced the term 
“dry eye”.3 For many decades, DED was thought to be limited to dryness of the 
eyes due to reduction of the aqueous phase of the tear film. In 1995, DED was 
defined as a complex multifaceted group of medical and ocular diseases that is 
due to decreased tear production and/or increased tear evaporation.4 In 2007, the 
International Dry Eye Workshop (DEWS) revised the original definition and clas-
sification scheme of DED and developed a new definition, as well as a three-part 
classification of DED based on etiology, mechanism, and severity of the disease.5 
The new definition of dry eye is “Dry eye is a multifactorial disease of the tears and 
ocular surface that results in symptoms of discomfort, visual disturbance, and tear Clinical Ophthalmology 2009:3 406
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film instability with potential damage to the ocular surface. 
It is accompanied by increased osmolarity of the tear film 
and inflammation of the ocular surface.” Additionally, DED 
can be categorized as episodic or chronic. Episodic dry eye 
occurs when environmental or visual tasks with reduced 
blinking overwhelm the stability of the tear and produce 
symptomatic dry eye. Chronic dry eye, although aggravated 
by the same environmental conditions, persists continuously 
with symptoms and possible damage to the ocular surface.6 
Because the tear film in dry eye patients is unstable and 
incapable of maintaining the protective qualities that are 
necessary for its structure and function, patients experience 
the discomfort symptoms associated with dry eye, which are 
burning, stinging, grittiness, foreign body sensation, tearing, 
ocular fatigue, and dryness.7 Patients may complain of 
symptoms of dry eye in the presence or absence of signs of 
the disease. Additionally, dry eye may be diagnosed based 
only on the signs observed by a healthcare professional in 
the absence of symptoms/complaints by the patients.
Demographics of dry eye
Dry eye disease is seen with increased prevalence in patients 
with autoimmune diseases,8 which affect approximately 8% 
of the population, of whom 78% are women.9 Dry eye disease 
also affects postmenopausal women10 and the elderly.11,12 
The prevalence of DED is estimated to be 7.4% to 33.7%12,13 
depending on which study is cited, how the disease is diag-
nosed, and which population is surveyed. The Beaver Dam 
population-based study found the DED prevalence rate to be 
14% in adults 48 to 91 years of age.11 The study also found 
that DED affects more women than men (16.7% versus 
11.4%, respectively). Reliable epidemiological studies from 
the large Women’s Health Study and Physician’s Health 
Study indicate that the prevalence of symptomatic dry eye 
in the United States is about 7% in women and 4% in men 
over the age of 50 years.10 These numbers translate into 
approximately 3.2 million women and 1.05 million men with 
DED in the United States.14 Estimates of those affected by 
DED of any severity amount to approximately 20 million 
or more in the United States alone.15 Likewise, international 
epidemiological studies report similar or higher rates around 
the world. The prevalence of DED is approximately 7.4% 
in Australia, with significant increase of prevalence in older 
patients and a significant decrease of tear production in 
women 50 to 59 years of age.13 In Indonesia, dry eye preva-
lence is approximately 27.5%, with increased prevalence 
associated with age, cigarette smoking, and pterygium.16 In 
Taiwan, the prevalence of DED is 33.7% in a tested elderly 
population, with significantly more women reporting dry 
eye symptoms than men.12 The prevalence of dry eye is 
also estimated at 25% in Canada17 and 33% in Japan.18 It is 
worth noting that the prevalence and incidence of DED, in 
the clinical setting, may also be under-reported, as patients 
may fail to recognize the symptoms of DED or do not report 
the problem to a physician.
Etiology and risk factors 
of dry eye disease
The last decade brought about a significant improvement 
in the understanding of the etiology and pathogenesis of 
DED. One major advance in the understanding of DED is the 
recognition of the two distinct components of the disease–tear 
evaporation and insufficient tear production–and their roles 
individually or concomitantly in DED.19 Another improve-
ment is the identification of tear film instability as a common 
feature of the various stages of DED and the realization that 
the thickness of the lipid layer might determine the stability 
of the tear film.20 Additionally, appreciation of the role of 
inflammation in DED was one of the most important factors 
that aided in the understanding and treatment of DED. The 
findings of the association of inflammation with reduced tear 
secretion and subsequent damage to the ocular surface led to 
the proposal of a unified concept of DED.21
Several risk factors for the development of DED have 
been identified repeatedly in epidemiological studies 
(Figure 1), such as increasing age and female sex (particularly 
postmenopausal women). In clinical experience, meno-
pausal and postmenopausal women both tend to have dry 
eye symptoms; this can be attributed to the significant 
decrease of tear production around the sixth decade of life 
in women.22 Hormonal studies suggest that sex hormones 
influence ocular surface conditions through their effects on 
tear secretions, meibomian gland function, and conjunctival 
goblet cell density. Conner and colleagues23 pointed out that 
women who were taking oral contraceptives had significantly 
higher goblet cell density than those who were not taking 
oral contraceptives. Krenzer and colleagues reported that 
chronic androgen deficiency is associated with meibomian 
gland dysfunction. Schaumberg and colleagues and Uncu 
and colleagues reported that postmenopausal women who 
use hormonal replacement therapy (HRT) have a higher 
prevalence of DED compared with those who have never 
used HRT.24–26 This was particularly true for women who 
used estrogen alone. Likewise, Smith and colleagues noted 
that women with primary ovarian failure developed clinically 
significant DED.27Clinical Ophthalmology 2009:3 407
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Other factors that precipitate and/or exacerbate DED 
include long-term contact lens wear, as it desensitizes 
the cornea over years of contact lens stimulation. Certain 
systemic medications, such as some antihistamines and 
antidepressants, have drying side effects, which can exacer-
bate or lead to dry eye.7 For several months after refractive 
surgery such as laser-assisted in situ keratomileusis (LASIK) 
or photorefractive keratectomy (PRK), patients may experi-
ence significant dry eye due to the severing of the corneal 
nerves during surgery.28,29
Furthermore, DED can be influenced through vari-
ous daily activities and social and dietary habits such as 
smoking, which increases the frequency of DED,16 and 
the dietary intake of omega-3 fatty acids, which reduces 
the incidence of DED.30 Extended visual tasking during 
computer use, television watching, and prolonged reading 
provoke symptoms of dry eye.31 Moreover, Schindelar and 
colleagues reported on the diurnal variations in the symp-
toms of dry eye.32 The exacerbation of the symptoms was 
dependent on the activities done at the time. For example, 
patients complaining of exacerbation of dry eye symptoms 
in the evening had reported driving, reading, and watching 
television in the evening.
Effects of the climate  
on dry eye disease
In addition to the above-mentioned etiologies and risk 
factors, climate and environmental challenges, such as 
relative humidity (RH), indoor environment, pollution, air 
travel, and extreme temperatures, among others, play a role 
in the prevalence of DED. A number of studies have shown 
an association between low RH and increased prevalence 
of DED, and that an increase of RH will result in fewer 
complaints of dry eye. Both RH and temperature influence 
the overall thermal climate and its effect on the precorneal 
tear film, and, thus, dry eye symptoms. Low RH conditions 
(office environment, air conditioned cars, airplane cabins, and 
extreme hot or cold weather) negatively impact the tear film, 
whereas an increase of RH leads to a more stable tear film, 
and, thus, more protection against desiccation of the eye.33,34 
Kjæregaard and colleagues35 reported that low ambient 
temperature and high RH are associated with more tear film 
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Figure 1 Dry eye cascade. Causes and contributing factors of abnormal tear film.
Abbreviations:   TFBuT, tear film break-up time; LASIK, laser-assisted in situ keratomileusis.Clinical Ophthalmology 2009:3 408
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stability than low RH and high temperature.35 Therefore, it is 
recommended that the indoor air should be “dry and cool,” 
with a RH of about 40%, which is better for the eyes than a 
RH below 30%.36 Outdoor air quality and temperature also 
affect tear film stability. Exposure to sun, dust, and wind 
exacerbate or precipitate DED.37 In the Women’s Health 
Study, Schaumberg and colleagues reported that women from 
the southern United States had a high prevalence of DED.25 
These indoor and outdoor factors can lower the quality of 
life and productivity of dry eye patients.
Effect of dry eye on the quality 
of life
The burden of DED to the patient is not trivial. Studies 
suggest that DED can have a considerable impact on visual 
function, daily activities, social and physical functioning, 
workplace productivity, direct and indirect cost of the 
disease, and quality of life (QOL).38,39 A reduction in QOL 
is inevitable when the symptoms of dry eye occur, whether 
they are mild, transient irritations or persistent symptoms. 
Schiffman and colleagues used utility assessment scores to 
quantify the QOL of DED patients.40 A perfect health has a 
utility score = 1.0, whereas death has a utility score = 0. The 
closer the utility score is to 1.0, the better the QOL. Compared 
with other diseases, mild dry eye had a utility score of 
0.81, compared with a utility score of 0.89 for psoriasis. 
Moderate dry eye had a utility score of 0.78, which is in the 
same range reported for moderate angina (0.75). Severe dry 
eye and dry eye requiring tarsorrhaphy had utility scores 
of 0.72 and 0.62, respectively. The former score corre-
sponds to class III/IV angina (0.71) and the latter is worse 
than disabling hip fracture (0.65). These low utility scores 
emphasize the burden and negative impact of DED on QOL, 
and, in a way, may explain why in the United States alone, 
approximately 7 to 10 million Americans use artificial 
tear preparations, with consumer spending estimated to be 
US$320 million per year.41
Physiology and function  
of the tear film
The healthy tear film contains a mixture of lipid, aqueous, 
and mucin (Figure 2). Prior to 1994, it was believed that 
the tear film was a sandwiched layer of lipid, aqueous, and 
mucin.42 A more recent model of the tear film is described 
as an interactive hydrated mucin gel, with lipid present 
not only on the surface of the tear film, but also associated 
with proteins that are distributed throughout the gel.43 The 
moisture of the eye, which is essential for optical and physi-
ological reasons, is maintained by the secretions of lipid, 
aqueous humor, and mucous. Lipids prevent evaporation 
and stabilize the tear film. Any disruption of oil secretion 
results in increased evaporation and destabilization of the 
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Figure 2 Healthy tear film with lipid, aqueous, and mucin layers and healthy ocular surface with intact microvilli.Clinical Ophthalmology 2009:3 409
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tear film, and, subsequently, DED. The aqueous layer makes 
up the bulk of the tear film and provides essential nutrients 
and oxygen to the avascular cornea, assists in the removal of 
metabolic wastes and debris, protects the ocular surface by 
carrying bacteriolytic enzymes and proteins, and provides 
the ocular surface with moisture. Reduced aqueous secre-
tion due to decreased production or increased evaporation 
leads to DED. Mucin creates a smooth hydrophilic barrier to 
the corneal epithelium for wetting of the ocular surface and 
protection from desiccation. Reduction in mucin secretion 
due to inflammation or trauma reduces tear film stability, 
potentially causing severe DED.7 In addition, inferior lid 
laxity, ectropic lid margin, incomplete lid closure, decreased 
blinking frequency, or incomplete blinking lead to functional 
dry eye despite normal tear film layers.44 A compromised 
tear film can lead to damage of the corneal and conjunctival 
epithelium with the resultant discomfort symptoms associ-
ated with dry eye (Figure 3). In general, all the intrinsic and 
extrinsic etiology and risk factors that lead to or exacerbate 
DED lead to unstable tear film due to the disruption of the 
structure or function of one or more of its layers. Clinicians 
usually rely on patients’ history along with other tests to diag-
nose DED, such as subnormal Schirmer testing, supravital 
staining of the ocular surface, and reduced tear film break-up 
time (TFBuT), among others.
Therapeutic options for dry 
eye disease
The first step in managing the disease is to identify the 
underlying etiology and to try to eliminate it and/or treat it. 
Afterward, and regardless of the etiology, the mainstay first-
line therapy is external augmentation of the tear film with 
topically administered artificial tear substitutes. Currently, 
there are numerous formulations on the market attempting 
to enhance tear film stability and increase TFBuT; however, 
many have been found to only temporarily relieve the 
symptoms of dry eye45 rather than to heal the ocular surface 
or treat the underlying cause of the disease. Artificial tears 
are typically buffered solutions that contain electrolytes, 
surfactants, preservatives (not all formulations), and a 
viscosity agent that is intended to increase the residency time 
of the drop.46 Although most artificial tears contain similar 
ingredients, they differ in the type of lubricant used, in their 
chemical properties, and in the type (or the lack thereof) of 
the preservative used.47 A review of the various formulations 
is discussed and presented by Murube and colleagues.48,49
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Figure 3 Progressive damage of corneal surface cells (lost microvilli) due to unhealthy tear film.Clinical Ophthalmology 2009:3 410
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Recent technologies in artificial tear formulations have 
focused on improving the shortfall (transient nature) of 
earlier formulations. The main role of osmolytes added to 
artificial tear formulations, such as in Optive® (Allergan, Inc., 
Irvine, CA, USA), is to provide osmoprotection of  the ocular 
surface against the high osmolarity of the tear film present 
in DED. When used concomitantly with cyclosporine 0.05% 
(Restasis®, Allergan, Inc.), Optive® improved TFBuT.50 
Addition of lipids to artificial tears aims to enhance tear 
film stability. Soothe® (Bausch and Lomb, Rochester, NY, 
USA), which is a metastable lipid emulsion, increased lipid 
layer thickness after 1 minute of instillation and improved 
dry eye symptoms in patients after application for one 
month.51 Another technology that protects the ocular surface 
by stabilizing the tear film and increasing the TFBuT is the 
hydroxypropyl (HP) guar-based molecule present in Systane® 
(Alcon Laboratories, Inc., Fort Worth, TX, USA). Original 
Systane® works well as a monotherapy to prolong TFBuT 
and protect the ocular surface and as an adjunct therapy to 
enhance the effect of cyclosporine A in the treatment of 
DED.52,53 Systane® Ultra (Alcon Laboratories, Inc.) is the 
newest addition to the market. The pH of Systane® Ultra 
is 7.9, which allows HP-Guar and borate to form a loosely 
cross-linked matrix in the bottle. The addition of sorbitol in 
this formulation controls the cross-linking, delivering the 
solution to the eye while providing the lasting properties of 
a gel. This results in prolonged comfort without a momentary 
blurring of vision. Moreover, Systane® Ultra works in concert 
with the natural divalent ions in the tear film (calcium, zinc, 
and magnesium), which strengthen the dynamic cross-linking 
of HP-Guar and borate and allow the tear film to mimic that 
of healthy eyes; this is important since, on average, there are 
7,000 to 10,000 blinking events every day, and the tear film 
must remain stable between blinks.
Restasis® is the only prescription drug in the United States 
for the treatment of DED. It is indicated for patients whose 
tear production is presumed suppressed due to ocular inflam-
mation; as such, it targets chronic inflammation-related DED. 
Restasis® statistically significantly increased Schirmer test 
scores in 15% of the patients, whereas increased tear production 
was not seen in patients using topical anti-inflammatory drugs 
or punctal plugs.54 The package insert states “Restasis® can be 
used concomitantly with artificial tears allowing a 15-minute 
interval between products.” Restasis® + original Systane® 
was statistically significantly better than Restasis® + Refresh 
Tears® (Allergan, Inc.), another artificial tear formulation; in 
fact, the original Systane® alone was better than Restasis® + 
Refresh Tears® at increasing TFBuT 6 months after initiation 
of therapy.53 Therefore, the appropriate choice of concomitant 
therapy used with Restasis® will have significant effects on 
outcome measures.
Clinical perspective
Eye care practitioners now recognize DED and its associated 
complications as not only one of the most common conditions 
seen in the office, but also one that significantly affects QOL. 
In the past, lectures about DED were given on the last day of 
medical conferences to nearly empty rooms, but this is not 
the case any longer. Once the medical and pharmaceutical 
communities recognized the impact DED has on people’s 
daily lives and on patients undergoing ocular surgery, several 
treatment modalities and options were made available. It is 
important to note that because DED is highly prevalent in 
women, who make most of the healthcare decisions for their 
families, when an eye care provider treats a woman’s DED, 
additional family members frequently come to the practice 
seeking help.
It is imperative that clinicians take a comprehensive 
approach in managing DED and its associated conditions 
by treating the various potential contributing factors of 
the disease. First, environmental changes, such as advis-
ing patients to wear glasses that decrease evaporation of 
tears; adjusting air vents at home, in the office, and in 
cars; adjusting ceiling fans; and controlling humidity, 
should be recommended. Second, patients should be 
advised to discontinue or avoid exposure to tobacco 
smoke, which destabilizes the tear film and decreases tear 
production. Third, patients should be encouraged to make 
dietary changes as well, such as reducing alcohol inges-
tion because it causes dehydration and exacerbates DED. 
Omega-3 oils, fish oil, and flaxseed oil can improve the 
tear film and decrease the inflammation associated with 
DED; therefore, patients should be advised to add these 
elements to their diets. Fourth, avoiding systemic diuretics 
and antihistamines, if possible, can significantly improve 
DED. Finally, because benzalkonium chloride, the most 
frequently used preservative in ophthalmic solutions, 
destabilizes the tear film and damages epithelial cells, 
it is prudent to encourage patients to use as few topical 
medications as possible. Clinicians may opt to change 
patients’ prescription to preservative-free formulations, 
such as Vigamox® or unit-dose Timolol®, or formulations 
with an alternative preservative, such as that found in 
Travatan Z®, Alphagan® P, or Systane® Ultra whenever 
possible. When a patient is not responding well to envi-
ronmental and lifestyle changes, and/or the use of artificial Clinical Ophthalmology 2009:3 411
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tears, Restasis® and a course of topical steroids should be 
added to the artificial tears regimen. Steroids help control 
DED-associated inflammation, but they should not be used 
long term because of their possible role in elevating IOP 
and causing cataracts. The two main issues associated with 
the use of Restasis® are burning, which is very significant 
in some patients, and the relatively long onset of action 
that does not provide immediate relief. Restasis® is very 
useful, however, in long-term control of DED. Restasis® is 
to be used twice daily and be supplemented with artificial 
tears. In a small percentage of patients, these combinations 
are sometimes insufficient. In these cases, punctal plugs 
or cautery should be considered.
Because DED is so prevalent and has such a significant 
impact on finances and quality of life, many pharmaceutical 
companies are working on other treatments options, some of 
which will be available in coming months. The ability of a 
physician to alleviate suffering, enhance QOL, and improve 
surgical outcomes in the vast majority of DED patients results 
in happier patients and better practices.
Conclusion
DED is a prevalent, multifactorial disease that is particularly 
frequent in elderly patients and women, especially meno-
pausal and postmenopausal women. DED can be episodic 
with transient signs and symptoms or chronic with persistent 
signs and symptoms. DED has a significant impact on visual 
function that can negatively impinge on the patient’s quality 
of life and productivity. Selection of the appropriate topi-
cal therapy should include consideration of the underlying 
cause of the disease, age and sex of the patient, concomitant 
medications such as antihistamines or hormonal replace-
ment therapy, and presence or absence of inflammatory eye 
disease. As we continue to learn about DED, and with the 
emergence of new therapies, the quality of life of women, 
elderly patients, and all other patients suffering from DED 
will be improved.
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